• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Health plans prepare for legislation to pass

Article

While the U.S. House and Senate wrangle over the final healthcare bill, health plans aren't sitting idly by waiting for the future to arrive.

While the U.S. House and Senate wrangle over the final healthcare bill, health plans aren’t sitting idly by waiting for the future to arrive. There are a number of trends plans can expect to affect business in 2010 and beyond.

The economy is still a wild card, but is showing signs of recovery. If the economy does improve, and more jobs are created, then health plan membership will also improve. If the economy doesn’t continue to improve, health plans must be prepared to focus even more on retaining and attracting members, according to Tom Epstein, vice president for public affairs, Blue Shield of California.

“Health plans need to develop products that are easy to understand and administer to prepare for the exchange environment,” he says. “We must also take strong action to hold the line on costs while improving care coordination and incentivizing quality care.”

Epstein says health plans will continue to seek partnerships and try new programs and technologies to improve the quality of care and lower costs.

“At Blue Shield we are piloting a new program with a medical group and a hospital where we all share the risk for providing coordinated care at a lower cost for a major customer,” he says. “Health plans will also bring more processes online to provide faster and more accurate service at a lower cost.”

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.